New Agreement Set to Scale Up Production of Hem A Gene Therapy
Hemophilia News Today by Marta Figueiredo, PhD | June 20, 2022 ASC Therapeutics has joined forces with Charles River to scale the manufacturing of ASC618, its second-generation virus-based gene therapy for hemophilia A. The agreement expands upon their current collaboration, begun in 2019 that focused on achieving Good Manufacturing Practice (GMP)-virus manufacturing and establishing processes for adeno-associated virus (AAV) production and … Read more